Sitemap - 2025 - The Microdose

AtaiBeckley patents R-MDMA formulation, and California issues a shrooms edibles warning

Little people hallucinations: 5 Questions with mushroom researcher Colin Domnauer

Federal legislators try again on psychedelics legislation; New Mexico to launch psilocybin program a year early; and Mapping psilocybin in the brain with…rabies?

Who discovered serotonin? 5 Questions with neuropharmacologist Patricia Whitaker

Federal government announces new funding for psychedelics; New Jersey advances psilocybin bill and New Mexico holds first public psilocybin meeting; Government increases 2026 psychedelics quotas

Psychedelic Church vs. State of Utah

Getting help with ketamine addiction: 5 questions for Ket-a-Grip’s founder

Psychedelics and the mind’s eye: 5 Questions for aphantasia researcher Joel Pearson

Pilot who attempted to cut plane engines after shrooms trip avoids prison time, and LSD microdoses not more effective than placebo in treating depression

Psychedelics for Anorexia?

What is psychedelic therapy really like? 5 Questions with the director of Psychedelic Lived Experiences Pedram Dara

Closed-door MAHA summit discusses psychedelics, Maryland task force recommends psilocybin program, and New Oregon psilocybin rules

In Texas’s Peyote Gardens

How alive is the world? 5 Questions on animism for anthropologist of religion Justine Quijada

Could psilocybin be the first FDA-approved psychedelic? Australia to fund psychedelic-assisted therapy for veterans; No differences between microdosing and placebo for mood and cognition

Mice on Magic Mushrooms

Ritalin-assisted therapy: 5 Questions for historian of pharmacy Lucas Richert

Mindbloom sued for wrongful death of 27-year old, and preliminary results for Delix’s non-hallucinogenic 5-MeO-DMT analog

A Navy SEAL goes to Mexico to take ibogaine

Journaling through the trip: 5 Questions for ALTERD app founder Sam Suchin

Breakthrough therapy designation for atai/Beckley 5-MeO-DMT drug; both ketamine and active placebo improve depression symptoms; and ketamine company to receive priority FDA review

Was Ayahuasca Used for Political Indoctrination in Brazil?

Mushrooms in the mountains of Oaxaca: 5 Questions for Documentary Filmmakers Mónica Álvarez and Tatiana García

Ibogaine researcher Nolan Williams dies at 42; DOI and DOC use in the U.S. rare; Money, power, and hostility in psychedelics

An Ayahuasca Message

Patented formulation of MDMA receives federal “Investigational New Drug” status; Intravenous ketamine outperforms esketamine

Was it DMT? Or was it heaven?

Compass’s patented-psilocybin trigger laws: 5 Questions for Porta Sophia’s Jeremy Rolquin and Shahin Shams

Psilocybin doesn’t help depression in pregnant rats; Mushrooms independently evolved ability to produce psilocybin twice; California psychedelics-related bill awaits governor’s signature

The Psychedelic Playlist

A Priest, a Rabbi, and a Muslim Leader Get High

Real-world psychedelics data: 5 Questions for public health researcher Kari Rockhill

Some “psilocybin” gummies contain no psilocybin, Pennsylvania holds hearing on COMPASS psilocybin trigger law

Announcing season 2 of the Altered States podcast!

Myth-busting psychedelics in ancient Greece: 5 Questions for religious studies professors Sharday Mosurinjohn and Richard Ascough

Response to the Lykos CRL; How big does an LSD dose need to be to quell anxiety?; and Psilocybin-assisted therapy results, 5 years later

Psychedelics for Postpartum Depression: 5 Questions for OB-GYN Camille Hoffman

FDA makes public its letter to Lykos on MDMA bid; U.S. military adds psilocin to active duty drug testing; Mississippi looks to join the ibogaine train

Pharmaceutical company AbbVie to buy Gilgamesh depression drug program for up to $1.2 billion; Kentucky committee discusses ibogaine; and Colorado listening session on Natural Medicine Program

Psilocybin rescheduling petition now with Department of Health and Human Services; Did ancient peoples in Greece and India partake in psychedelics?; Germany approves “compassionate use” psilocybin

The Trip Chauffeur: 5 Questions for Sunshine Rides’ Alan Currie

The Future of State Psychedelic Policy: 5 Questions for attorney Dave Kopilak

Hallucinogen use on the rise nationally; What do Oregon’s psilocybin stakeholders want?

The Molly Maker: 5 Questions for PharmAla founder Nick Kadysh

Trump’s pick to lead the DEA gets confirmed; FDA opens “priority voucher” for new drugs; and Inhalable DMT research remains on hold

Inside the Church of Gaia’s DEA exemption: 5 Questions for attorney Taylor Loyden

Psilocybin’s effects on human cell and mouse aging; Cancer patients treated with psilocybin show decreased depression and anxiety symptoms

A New Psychedelic Mushroom Gets the Artistic Treatment

Beckley announces new results for 5-MeO-DMT drug; Updates on psychedelics and the Trump Administration; Data and lessons from Health Canada’s psilocybin access program

Don Quixote, DMT, psychedelic tourism: 5 Questions for literature professor Alberto Ribas-Casasayas

Compass announces Phase 3 synthetic psilocybin results; DEA moves two psychoactive research chemicals to Schedule I; and New Zealand Ministry of Health approves prescription psilocybin

The art of relinquishing control: 5 Questions for artist Matthew Palladino

Live from Psychedelic Science 2025

Psychedelic Science 2025

Live from Psychedelic Science 2025: A dispatch from Denver

Shamanism and psychedelics: 5 Questions for Manvir Singh

Texas passes nation’s first ibogaine research funding bill; Colorado’s first Natural Medicine client; and Psilocybin’s effects wane a year after dosing

MDMA for narcissism? 5 Questions for psychoanalyst and psychiatrist Alexa Albert

Ketamine company sues newspaper; atai to merge with Beckley Psytech; and Oregon disabilities case continues

Psychedelic traditions from Africa and the African diaspora: 5 Questions for Darren Le Baron

Meta suspends numerous psychedelics-related accounts; California psilocybin pilot program bill dies; and Preliminary results from Gilgamesh’s phase 2 clinical trial

FDA commissioner says psychedelics are a “top priority,” and Connecticut legislators just barely pass decrim bill

The Acid Queen

Colorado’s Natural Medicine program launches, and Texas goes all in on psychedelics

Florida legislature votes to ban psilocybin mushroom spores and Colorado legislators pass data collection bill; Federal leaders continue advocacy of psychedelics

"Recovery is whatever makes you feel less bad": 5 Questions for The Small Bow founder A.J. Daulerio

RFK Jr.’s first acid trip, and federal health leaders appear to be keen on psychedelics; The rise of ketamine use disorder

Treating patients with challenging psychedelics experiences: 5 Questions for psychiatrist Azin Bekhrad

Increase in psilocybin use — and in poison control reports; Could classic psychedelics reduce stress-induced inflammation?; A study of Nova festival survivors

A non-hallucinogenic LSD analog?; Texas committee advances ibogaine research grant bill; Psyence bets on ibogaine

Taking the drug out of the trip: 5 Questions for Stanford anesthesiologist and neuroscientist Boris Heifets

New Mexico becomes third state to establish a state psilocybin program; Federal bill to improve veteran access to psychedelics; DOGE eliminates 10,000 HHS positions

Colorado’s first licensed healing center: 5 Questions for The Center Origin co-founder and clinical director Mikki Vogt

Veterans Affairs Secretary vows to “get to the yes” on psychedelics; Colorado licenses first psilocybin healing center; Perceived effects of psychedelics on sex

Psilocybin for anorexia: 5 Questions for researcher Marissa Raymond-Flesch

Minnesota introduces psilocybin decriminalization bill, and wide-ranging Florida bill would ban psilocybin mushroom spores and mycelia; One dose of psilocybin equivalent to placebo in decreasing alcoh

The power of “know-cebo”: 5 Questions for data scientist Balázs Szigeti

New Mexico poised to become third state with a regulated psilocybin program; Low doses of LSD for ADHD no more effective than placebo; State bill bonanza continues

Taking ayahuasca with mom: 5 Questions for NFL safety Jordan Poyer

Not everything’s bigger in Texas

“You can be humbled by a trip”: 5 Questions for Zen Buddhist priest Kokyo Henkel

New bills in CT and VT, bills advance in AZ and MO, and a NV resolution; Oregon psilocybin center wins permit appeal; and A bad trip case study

Foragers and “noccers”: 5 Questions for mycologist and author Eugenia Bone

New California bills focus on veterans; the State of Psychedelics; Death penalty for dealers?

What do people see when they’re tripping?: 5 Questions for neuroscientist Sean Noah

Federal court sides with DEA’s denial of access to psilocybin for terminally ill patients; COMPASS trigger law in Kansas; Could Arizona be first on ibogaine?

RFK Jr. confirmed as Trump’s health secretary; Federal lawsuit against Oregon’s psilocybin program; Changing psilocybin laws in India?

Spiritual crisis and psychedelics: 5 Questions for anthropologist Aidan Seale-Feldman

A flurry of new state bills; Preliminary synthetic 5-MeO-DMT phase II results; Lessons from a suicide

Black Psychedelia: 5 Questions for author Nick Powers

Kennedy hearings; U.S. Embassy in Peru & Costa Rica Ministry of Health warn against ayahuasca use; Proposed legislation would change OR & CO psilocybin programs

Sex & Psychedelics: 5 Questions for magazine founder Sura Hertzberg

FDA expands Spravato approval, and the Future of RFK Jr. and federal agencies' approach to psychedelics in limbo

Lykos board shake-up; Colorado’s Natural Medicine program weighs new at-home facilitation rules; LSD for mind control

Ayahuasca in China, Peru, and Australia: 5 Questions for anthropologist Alex Gearin

Billionaire proposes plan to take control of Lykos; Colorado’s Natural Medicine Program launches; Could Minnesota be next?; Mail-order ketamine for injection

The risks of mixing ayahuasca and SSRIs: 5 Questions for UCLA psychiatry professor Charles Grob

What is one psychedelics story you will be following in 2025?